Tirzepatide for Obesity
Verdict: Published with Warning
Across 5 PubMed studies, the evidence for Tirzepatide in Obesity grades Tier A — moderate evidence. Effective, but with safety or population caveats.
A 🔵 A Moderate Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.76
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
A · Published with Warning
Confidence
89%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.76
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (5)L2 · primary research & systematic reviews
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)
Finding: At 72 weeks tirzepatide produced significantly greater weight loss than semaglutide: -20.2% vs -13.7% (P<0.001), a ~6.5-percentage-point superiority in adults with obesity but without diabetes.
View on PubMed Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Finding: At 72 weeks dose-dependent weight loss of -15.0% (5mg), -19.5% (10mg) and -20.9% (15mg) vs -3.1% placebo (P<0.001 all); 85-91% of tirzepatide patients lost >=5% vs 35% placebo.
View on PubMed Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including SURMOUNT-2
Finding: Pooled across 7 RCTs (n=4,795), tirzepatide reduced body weight vs placebo dose-dependently by -8.07% (5mg), -10.79% (10mg) and -11.83% (15mg), with GI events the most common, mostly mild-moderate and transient.
View on PubMed Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis
Finding: Across ~5,800 patients tirzepatide lowered weight by MD -12.47 kg vs placebo and modestly outperformed semaglutide (MD -1.90 kg, 95% CI -2.97 to -0.83); 78%/56%/32% reached >=5%/>=10%/>=15% loss.
View on PubMed Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials
Finding: Pooling 12 RCTs (n=11,758) tirzepatide reduced weight vs placebo (MD -3.99) and vs GLP-1 RAs (MD -1.71, 95% CI -2.46 to -0.95), with a 30-fold higher chance of >=20% weight loss vs placebo (RR 30.43) but more GI adverse events.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Supportive
MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. WARNING: RISK OF THYROID C-CELL TUMORS — Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell … source↗
L4b EU EFSA
Supportive
Mounjaro received a marketing authorisation valid throughout the EU on 15 September 2022. The active substance in Mounjaro, tirzepatide, acts in the same way as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Mounjaro is a prescription-only medicine indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct… source↗
L4c UK NHS
Supportive
Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index (BMI) of at least 35 kg/m2 and at least 1 weight-related comorbidity. If less than 5% of the initial weight has been lost after 6 months on the highest tolerated dose, decide whether to continue tre… source↗
L4d TW TFDA / 衛福部
Supportive
猛健樂注射劑15毫克/0.5毫升 (MOUNJARO Injection 15mg/0.5mL)；許可證字號：衛部藥輸字第028468號；限由醫師使用；適應症：(1) 作為飲食及運動療法之外的輔助治療，用於改善第二型糖尿病成人病人之血糖控制；(2) 作為飲食及運動療法之外的輔助治療，用於體重控制（肥胖或過重）；申請商：台灣禮來股份有限公司；發證日期：112-07-19 source↗
L4e WHO
Supportive
Tirzepatide (GLP-1/GIP dual receptor agonist) used as glucose lowering therapy for adults with type 2 diabetes mellitus with established cardiovascular disease or chronic kidney disease and obesity. High prices of medicines like semaglutide and tirzepatide are limiting access to these medicines. source↗
L5a NIH Office of Dietary Supplements
Supportive
Tirzepatide functions as a dual agonist with greater affinity to GIP receptors than to GLP-1 receptors. FDA approvals: Type 2 Diabetes (Mounjaro) - May 2022 as adjunct to diet and exercise for glycemic control; Obesity (Zepbound) - November 2023 for chronic weight management in adults with obesity or overweight plus comorbidities; Obstructive Sleep Apnea (Zepbound) - December 2024 for moderate-… source↗
L5b Mayo Clinic
Supportive
Tirzepatide injection is used to treat type 2 diabetes and is used together with diet and exercise to help control your blood sugar. Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Additionally, tirzepatide injection is also used to help lose weight and keep the weight off in patients with obesity caused by certa… source↗
L5c Cleveland Clinic
Supportive
These medications are prescribed for chronic weight management in adults who have obesity or those who are overweight with a co-morbidity, like high blood pressure or high cholesterol. These medications have been shown to help patients lose 15% to 20% of their body weight. source↗
L5d Harvard Health
Supportive
the GLP-1/GIP agonist tirzepatide (Zepbound) mimics the hormone gastric inhibitory polypeptide (GIP), which has similar effects to those of GLP-1. ... participants receiving semaglutide or tirzepatide lost 15% to 20% of their body weight on average. source↗
L5e Specialty Society (condition-mapped)
Supportive
Overall, tirzepatide treatment resulted in significant weight loss, regardless of the number of obesity-related complications patients had at the outset of the study. source↗